Holen Sie sich die Stockscreener-App
65.93
0.92%
0.60
Vorhandelsmarkt:
67.34
1.41
+2.14%
Schlusskurs vom Vortag:
$65.33
Offen:
$64.682
24-Stunden-Volumen:
4.19M
Relative Volume:
1.47
Marktkapitalisierung:
$5.69B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-23.55
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
+25.03%
1M Leistung:
+48.99%
6M Leistung:
+49.16%
1J Leistung:
+17.23%
1-Tages-Spanne:
$61.13
$66.77
1-Wochen-Bereich:
$53.40
$71.13
52-Wochen-Spanne:
$30.04
$71.13
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
65.93 | 4.55B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Private Advisor Group LLC Increases Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
What drives CRISPR Therapeutics AG stock priceLightning-fast growth - Autocar Professional
CRISPR Therapeutics AG Stock Analysis and ForecastHigh-yield investments - jammulinksnews.com
Is CRISPR Therapeutics AG a good long term investmentAccelerated investment success - jammulinksnews.com
Research Analysts Set Expectations for CRSP Q2 Earnings - MarketBeat
Bank of America Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $78.00 - MarketBeat
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo.co
Crispr Therapeutics price target lowered to $78 from $79 at BofA - TipRanks
What analysts say about CRISPR Therapeutics AG stockDynamic profit expansion - jammulinksnews.com
CRISPR Therapeutics' Stock Surge: A Glimpse into the Future of Gene-Editing Investment - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Sees Large Volume IncreaseStill a Buy? - MarketBeat
CRISPR Therapeutics Rises Amid Gene Editing Breakthroughs - StocksToTrade
CRISPR Stock (CRSP) Continues to Sizzle on Insider Deal - TipRanks
Insider Buying: CRISPR Therapeutics AG (NASDAQ:CRSP) Director Buys 989,812 Shares of Stock - MarketBeat
3 Monster Stocks in the Making to Buy Right Now - The Motley Fool
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
Q2 EPS Estimate for CRISPR Therapeutics Lifted by Analyst - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.75 Average Price Target from Analysts - MarketBeat
Crispr Therapeutics AG Stock Soars Amid Insider Confidence - TipRanks
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - MSN
Is It Worth Investing in CRISPR Therapeutics (CRSP) Based on Wall Street's Bullish Views? - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 5.7%What's Next? - MarketBeat
CRSP’s Astounding Gains: Should Investors Jump In? - timothysykes.com
CRISPR Therapeutics (CRSP) Surges after Director Buys over $51M Worth of Shares - TipRanks
Crispr stock soars after director buys $51.5 million in shares - Investing.com
CRISPR Therapeutics Breaks Ground with Promising Phase 1 Trial Advances - timothysykes.com
CRISPR Therapeutics (NASDAQ:CRSP) Hits New 52-Week High Following Insider Buying Activity - MarketBeat
Crispr director George buys $51.5M of shares (CRSP:NASDAQ) - Seeking Alpha
Crispr Therapeutics stock hits 52-week high at 62.32 USD - Investing.com
Director Makes Multi-Million Dollar Investment in Crispr Therapeutics AG! - TipRanks
CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last? - MSN
Leavell Investment Management Inc. Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):